Caner Ediz

Caner Ediz

Auto-generated profile, based on publicly available information

Caner Ediz

Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
CECaner Ediz
Caner Ediz
HTHasan Huseyin Tavukcu
Hasan Huseyin Tavukcu
SASerkan Akan
Serkan Akan
YKYunus Emre Kizilkan
Yunus Emre Kizilkan
AAAdem Alcin
Adem Alcin
OYOmer Yilmaz
Omer Yilmaz
Aims This study aims to analyze the novel Coronavirus disease (COVID‐19) related testicular pain in hospitalized patients due to COVID‐19 and to review as an etiological factor for epididymitis, orchitis or both. Methods A total of 91 patients were included in the study. A questionnaire was formed for the questioning of testicular pain or epididymo‐orchitis in patients with COVID‐19. Demophrahics and past medical history was also recorded. Patients’ neutrophil and lymphocyte counts, neutrophil‐lymphocyte ratios (NLR), C‐reactive protein (CRP)levels and D‐dimer values were recorded. Patients with COVID‐19 were divided into two groups according to absence or presence of testicular pain or epididymo‐orchitis as group 1 and group 2. All results were compared for both groups. Results The median age of patients was similar in both groups. Testicular pain was occured in 10.98% of the patients. Clinical presentation of epididymo‐orchitis was diagnosed in only one patient. No statistically significant difference was reported in terms of patients’ age, levels of CRP and D‐Dimer or NLR and results of questionnaire form queries between the two groups (p>0.05). Conclusion Testicular pain was observed more frequently in hospitalized COVID‐19 cases. While no inflammation marker which is related to predict of testicular pain or epididymo‐orchitis was found in patients with COVID‐19.

5 November 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
SASerkan Akan
Serkan Akan
CECaner Ediz
Caner Ediz
ASAytac Sahin
Aytac Sahin
HTHasan Huseyin Tavukcu
Hasan Huseyin Tavukcu
AUAhmet Urkmez
Ahmet Urkmez
AVAyhan Verit
Ayhan Verit

5 March 2016 in Andrology
Verified
Journal Article
Closed access
PDF file
RAR. Altintas
R. Altintas
CEC. Ediz
C. Ediz
HCH. Celik
H. Celik
ACA. Camtosun
A. Camtosun
CTC. Tasdemir
C. Tasdemir
CAC. Alan
C. Alan

Verified
Journal Article
Open access
PDF file
CECaner Ediz
Caner Ediz
SASerkan Akan
Serkan Akan
MTMuhammed Cihan Temel
Muhammed Cihan Temel
OYOmer Yilmaz
Omer Yilmaz
Objective: In this study, we aimed to determine the predictive factor for additional treatment requirement in active surveillance (AS) for patients with low or very low-risk prostate cancer (PCa) and we investigated the effect of tumor burden by total core involvement rate in biopsy to predict of need for additional treatment. Material and methods: 107 patients with PCa in AS between 2005 and 2018 have been evaluated retrospectively. Groups were divided into two groups according to the need for additional treatment. Group 1 received additional treatment, group 2 did not receive additional treatments and active surveillance was continued. Patient’s total prostate-specific antigen (tPSA), prostate-specific antigen density (PSA-D), total core involvement count, quantity and rate at biopsy pathology results and follow-up period were recorded and compared in the two groups. Results: The current cohort includes 107 patients. Mean age at diagnosis was 63.01years. Mean tPSA values at diagnosis were 6.09 ng/mL and 5.2 ng/mL in the group 1 and group 2, respectively. Mean follow-up period was 38.1 months (range, 12 to 134 months). Only PSA-D measurement significantly predicted need for additional treatment (p = 0.017). ROC analysis showed that the optimal threshold was 0.13 ng/mL/cc (sensitivity: 70.8%; specificity: 57.1%). Additional treatment requirement was not detected in patients with PSA-D cut-off level less than 0.07 ng/mL/cc. Conclusions: Total tumor burden of less than 5% is safe for patients with low or very low-risk PCa in AS. A 0.13 ng/mL/cc cut-off level of PSA-D can predict to need for additional treatment in patients managed by AS.

1 April 2020 in Journal of the College of Physicians and Surgeons Pakistan
Verified
Journal Article
Closed access
MTMuhammed Cihan Temel
Muhammed Cihan Temel
CECaner Ediz
Caner Ediz
SASerkan Akan
Serkan Akan
EOEymen Ozer
Eymen Ozer
OYOmer Yilmaz
Omer Yilmaz
Objective: To analyse the association of prostate cancer (PCa) Gleason score evaluated upon prostate biopsy with clinical PSA values, total and free testosterone (TT and FT, respectively) levels measured prior to biopsy. Study Design: A descriptive study. Place and Duration of Study: Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, from July to December 2019. Methodology: A total of 85 patients were included and classified into non-PCa (group 1) and PCa (group 2) groups according the results of prostate biopsy pathology. Age, digital rectal examination (DRE) findings; prostate volume (PV); free/total prostate specific antigen (PSA) ratio (f/tPSA); PSA density (PSA-D) and total PSA (tPSA), free PSA (fPSA), TT and FT levels of the two groups were evaluated. Associations of the ISUP grade of patients in group 2 with age, DRE findings for PCa; PV; PSA-D; f/tPSA and tPSA, fPSA, TT and FT levels were analysed. Results: Mean patient age was 63.00 (57.50-70.00) years. Mean age, significant DRE findings for PCa, tPSA levels and PSA-D were significantly higher in group 2 (p <0.05), whereas PV was significantly higher in group 1 (p <0.05). The ISUP grade of patients in group 2 was significantly and positively correlated with age and tPSA levels (p <0.05). ISUP grade was significantly and positively correlated with significant DRE findings for PCa (p <0.05). However, ISUP grade was negatively correlated with PV and f/tPSA (p 0.05). Conclusion: TT and FT levels evaluated before prostate biopsy did not provide any additional benefit in predicting Gleason score grade before biopsy.

2 April 2020 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
SASerkan Akan
Serkan Akan
CECaner Ediz
Caner Ediz
HTHasan Hüseyin Tavukcu
Hasan Hüseyin Tavukcu
AOAlpaslan Ozgun
Alpaslan Ozgun
OYOmer Yilmaz
Omer Yilmaz
Background: The aim of this study was to examine clinical/pathological characteristics, prognosis and tendency to metastasis of mixed germ cell tumours (MGCTs) that contain a seminoma component. Methods: A total of 111 MGCT cases between 2008 and 2018 were retrospectively enrolled. The patients were divided into 2 groups according to the absence (group 1) or presence (group 2) of seminoma component in MGCTs. Patients’ age, complaints at admission to our clinic, primary tumour localization, primary tumour size, preoperative testicular tumour markers, MGCT histopathological components and percentages, lymphovascular invasion, pathological tumour stage, postoperative testicular tumour markers, presence of lymph node involvement in abdominal tomography, lung metastasis based on thorax tomography, clinical tumour stage, adjunctive therapies performed, state of recurrence and survival were compared in 2 groups. Results: The mean age of the patients was 24.51 ± 4.79 years. The mean age, initial complaint rates, primary tumour size, postoperative testicular tumour markers, presence of lymphovascular invasion, presence of lymph node involvement and lung metastasis were found to be higher in group 2 than in group 1, although these differences were not statistically significant. Especially, it was found that a seminoma component rate of 30% and higher had a higher tendency for a poor prognosis. Conclusion: Although the word “seminoma” may be initially interpreted as an indication of good prognosis, a seminoma component in MGCTs is actually not a good prognostic factor. MGCTs that contain a seminoma component (especially 30% and higher) can have a higher tendency for occult metastatic disease.